Melanie M. Frigault - Vincerx Pharma, Inc.

基本信息

Career Trajectory

Bio

Proven track record of strategic and scientific leadership to deliver decision making biomarker data for dose and schedule selection, understanding mechanisms of resistance for rationale-based combinations and to select the right patient/indication for pipeline clinical development.

Research Interests

Papers共 112 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Molecular Profiling Identifies CD49d and CD79b As Predictive Markers for Acquired Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia

Elena Bibikova, Sara Parsa,Muskan Floren, Brian Law,Tracy Clevenger,Jean Cheung,Gary De Jesus, Kathleen Burke,Michael Gulrajani,Kyoko Yamaguchi, Phuong Do,Brian Dougherty,David Whitston,Graham Brock,Veerendra Munugalavadla,Melanie M. Frigault,Tanja N. Hartmann,John C. Byrd,Richard R. Furman,Jennifer R. Brown,Todd Covey,Andrew Mortlock

HEMATOLOGICAL ONCOLOGYno. 1 (2025)

Cited0Views0WOSBibtex

Activity of VIP943 on AML Patient-Derived Leukemic Blasts and Healthy Donor-Derived Bone Marrow Hematopoietic Stem Cells

Beatrix Stelte-Ludwig,Tibor Schomber,Melanie M. Frigault,Joseph Birkett,Amy J. Johnson,Anne-Sophie Rebstock, Sebastian Ludwig,Raquel Izumi,Ahmed Hamdy

Cancer Researchno. 6_Supplement (2024): 629-629

Cited0Views0Bibtex

Abstract PO-008: Phase I/II Study of VIP152 (enitociclib), Venetoclax, and Prednisone (VVIP) in Relapsed/refractory (R/R) Lymphoid Malignancies

Christopher Melani,Max Gordon,Rahul Lakhotia,Stefania Pittaluga,Jillian Simard,Jagan Muppidi,James D. Phelan,Svetlana Pack,Amynah Pradhan,Candis Morrison,Atekelt Tadese, Anna M. Juanitez, Amy J. Johnson,Melanie M. Frigault, Ahmed Hamdy,Mark Roschewski,Louis M. Staudt,Wyndham H. Wilson

Blood Cancer Discoveryno. 3_Supplement (2024)

Cited0Views0Bibtex

Enitociclib, a Selective CDK9 Inhibitor: in Vitro and in Vivo Preclinical Studies in Multiple Myeloma

Son Tran,Patrick Sipila,Melanie M. Frigault,Beatrix Stelte-Ludwig,Amy J. Johnson,Joseph Birkett,Raquel Izumi,Ahmed Hamdy,Ranjan Maity,Nizar J. Bahlis,Paola Neri,Aru Narendran

Blood Neoplasiapp.100050, (2024)

Cited0Views0Bibtex

An Open-Label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Patients with Advanced CD123+ Hematologic Malignancies

Stephen Anthony Strickland, Emily K. Curran, Omer Hassan Jamy, Mary-Elizabeth Percival,Amy J. Johnson,Joseph Birkett,Xin Huang,Melanie M. Frigault, Hans-Georg Lerchen,Beatrix Stelte-Ludwig,Tasheda Navarro, Jim Peck, Wyatt Gross,Raquel Izumi, Ahmed M. Hamdy,Naval Guastad Daver

Journal of Clinical Oncologyno. 16_suppl (2024): TPS3167-TPS3167

Cited0Views0Bibtex

An Open-Label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, and Pharmacokinetics of VIP236 Monotherapy in Patients with Advanced Cancer

Andrae L. Vandross, Brian N. Stein, Jermaine Coward,Sunil Sharma,Amy J. Johnson,Joseph Birkett,Xin Huang,Melanie M. Frigault, Hans-Georg Lerchen,Beatrix Stelte-Ludwig,Tasheda Navarro, Jim Peck, Wyatt Gross,Raquel Izumi, Ahmed M. Hamdy, Ildefonso Rodriguez Rivera

Journal of Clinical Oncologyno. 16_suppl (2024): TPS3168-TPS3168

Cited0Views0Bibtex

Supplementary Figure from First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy

Jennifer R. Diamond,Valentina Boni,Emerson Lim,Grzegorz Nowakowski,Raul Cordoba,Daniel Morillo,Ray Valencia,Isabelle Genvresse,Claudia Merz,Oliver Boix,Melanie M. Frigault,Joy M. Greer,Ahmed M. Hamdy,Xin Huang,Raquel Izumi,Harvey Wong,Victor Moreno

openalex（2023）

Cited0Views0Bibtex

Table S2 from Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription

Melanie M. Frigault,Arushi Mithal,Harvey Wong,Beatrix Stelte-Ludwig,Vinay Mandava, Xin Huang,Joseph Birkett,Amy J. Johnson,Raquel Izumi,Ahmed Hamdy

crossref（2023）

Cited0Views0Bibtex

Figure S2 from Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription

Melanie M. Frigault,Arushi Mithal,Harvey Wong,Beatrix Stelte-Ludwig,Vinay Mandava, Xin Huang,Joseph Birkett,Amy J. Johnson,Raquel Izumi,Ahmed Hamdy

openalex（2023）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn